Hiv protease inhibitors useful for the treatment of aids
CA 2032259 A1 · Owner: Merck & Co. Inc. · Inventors: Lyle, Terry A.; Huff, Joel R.; Thompson, Wayne J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Compounds of the form A-G-B-B-J, wherein A is an amine protecting group or urethane, G a dipeptide isostere substituted with a basic amine nitrogen, B an amino acid or analog thereof, and J a small terminal group are described. These compounds are useful in the inhibition of HIV protease, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds 71/RDM40, - i - 18025IA, pharmaceutically acceptable salts pharmaceutical, composition ingredients whether or not in, combination with other antivirals immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 14, 1990. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 14, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 14, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.